Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.29 USD | -0.55% | -5.04% | +11.68% |
Financials (USD)
Sales 2024 * | 17.37M | Sales 2025 * | 86.5M | Capitalization | 1.43B |
---|---|---|---|---|---|
Net income 2024 * | -240M | Net income 2025 * | -179M | EV / Sales 2024 * | 77.5 x |
Net cash position 2024 * | 85.57M | Net cash position 2025 * | 186M | EV / Sales 2025 * | 14.4 x |
P/E ratio 2024 * |
-5.77
x | P/E ratio 2025 * |
-8.12
x | Employees | 174 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.31% |
Latest transcript on Day One Biopharmaceuticals, Inc.
1 day | -0.18% | ||
1 week | -6.77% | ||
Current month | -4.21% | ||
1 month | +13.91% | ||
3 months | +5.61% | ||
6 months | +45.99% | ||
Current year | +12.19% |
Managers | Title | Age | Since |
---|---|---|---|
Samuel Blackman
FOU | Founder | 55 | 18-10-31 |
Jeremy Bender
CEO | Chief Executive Officer | 52 | 20-08-31 |
Charles York
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 21-08-16 |
Natalie Holles
BRD | Director/Board Member | 51 | 21-01-31 |
John Josey
BRD | Director/Board Member | 63 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | +9.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 16.3 | -0.46% | 119 083 |
24-05-09 | 16.38 | -0.18% | 677,734 |
24-05-08 | 16.41 | -3.92% | 603,191 |
24-05-07 | 17.08 | +2.89% | 1,777,935 |
24-05-06 | 16.6 | -3.32% | 1,135,258 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.19% | 1.43B | |
+23.37% | 47.02B | |
+49.90% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- DAWN Stock